Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BLRX 
BioLineRx Ltd (BLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 18.76% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.85M USD | Price to earnings Ratio - | 1Y Target Price 160 |
Price to earnings Ratio - | 1Y Target Price 160 | ||
Volume (30-day avg) 36644 | Beta 0.93 | 52 Weeks Range 2.85 - 35.60 | Updated Date 04/2/2025 |
52 Weeks Range 2.85 - 35.60 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -90.57% | Operating Margin (TTM) -108.98% |
Management Effectiveness
Return on Assets (TTM) -32.96% | Return on Equity (TTM) -184.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11425387 | Price to Sales(TTM) 0.38 |
Enterprise Value 11425387 | Price to Sales(TTM) 0.38 | ||
Enterprise Value to Revenue 0.52 | Enterprise Value to EBITDA -0.67 | Shares Outstanding 3558500 | Shares Floating 1142506606 |
Shares Outstanding 3558500 | Shares Floating 1142506606 | ||
Percent Insiders 4.67 | Percent Institutions 1.41 |
Analyst Ratings
Rating 4.5 | Target Price 4.57 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioLineRx Ltd
Company Overview
History and Background
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on oncology. Founded in 2003, it develops and commercializes novel therapeutics. Milestones include partnerships with pharmaceutical companies and clinical trial advancements.
Core Business Areas
- Oncology: Focuses on developing therapies for cancer treatment, primarily hematological malignancies.
Leadership and Structure
The leadership team consists of the CEO, CFO, and Chief Medical Officer. The organizational structure includes R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Motixafortide (Aphexda): A CXCR4 inhibitor used in combination with filgrastim to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma patients. Approved by the FDA. Competitors include G-CSF and Plerixafor.
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and rapidly evolving, with a focus on oncology and novel therapies.
Positioning
BioLineRx Ltd. is positioned as a specialized oncology company with a focus on hematological malignancies. Its competitive advantage lies in its novel CXCR4 inhibitor technology.
Total Addressable Market (TAM)
The global multiple myeloma market is projected to reach billions of USD. BioLineRx Ltd. is positioned to capture a share of this market with its Aphexda.
Upturn SWOT Analysis
Strengths
- FDA Approved Product
- Novel Technology (CXCR4 Inhibition)
- Strong Clinical Data
- Strategic Partnerships
Weaknesses
- Limited Commercial Infrastructure
- Reliance on Partnerships
- Limited Number of Products
- Small Market Cap
Opportunities
- Expansion into New Indications
- Partnerships with Larger Pharmaceutical Companies
- Geographic Expansion
- Advancements in Cancer Research
Threats
- Competition from Established Pharmaceutical Companies
- Regulatory Hurdles
- Clinical Trial Failures
- Economic Downturn
Competitors and Market Share
Key Competitors
- AMGN
- SANOY
Competitive Landscape
BioLineRx Ltd. faces intense competition from larger pharmaceutical companies with established portfolios. Its competitive advantage lies in its novel CXCR4 inhibitor technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and partnership agreements.
Future Projections: Future growth is dependent on the commercial success of Motixafortide and potential expansion into new indications.
Recent Initiatives: Recent initiatives include FDA approval of Motixafortide and commercial launch preparations.
Summary
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focusing on oncology, primarily hematological malignancies, with a now FDA-approved product. The company's strength lies in its novel CXCR4 inhibitor technology, but it faces challenges due to its limited commercial infrastructure and dependence on partnerships. Success hinges on the commercial launch of Motixafortide and potential expansion into new indications, while closely managing regulatory risks and competition from larger pharmaceutical entities.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLineRx Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2011-07-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.biolinerx.com |
Full time employees - | Website https://www.biolinerx.com | ||
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.